Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00370292
Status:
COMPLETED
Last Update Posted:
2009-10-20
First Post:
2006-08-29
Brief Title:
Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer NSCLC
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients affected by non-small cell lung cancer NSCLC will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles Pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action Purpose of the trial is to monitor the blood values of these biomolecules at different time intervals to optimize the synergism between pemetrexed and gemcitabine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-IT-S105 | None | None | None |